ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 140 • 2016 ACR/ARHP Annual Meeting

    Relationship Between the Prevalence of Subclinical Tenosynovitis and Therapy in Patients with RA in Clinical Remission: Results from Italian Society of Rheumatology Study Group

    Simone Parisi1, Greta Carrara2, Carlo Alberto Scirè3,4, Alberto Batticciotto5, Emanuela Bellis6, Marco Canzoni7, Orazio De Lucia8, Ilaria Farina9, Carlo Venditti10, Annamaria Iagnocco11,12 and Georgios Filippou13, 1Department of Rheumatology, University Hospital Città Della Salute e della Scienza di Torino, Turin, Italy, 2Epidemiology Unit, Italian Society for Rheumatology, Milano, Italy, 3Epidemiology Unit -Italian Society for Rheumatology, Milano, Italy, 4Epidemiology Unit – Italian Society for Rheumatology (SIR), Milano, Italy, 5Rheumatology, L. Sacco University Hospital, Milano, Italy, 6Rheumatology, Ospedale Mauriziano, Turin, Italy, 7A.O. Sant'Andrea, Rome, Italy, 8Rheumatology, Orthopedic Institute Gaetano Pini, Milano, Italy, 9Rheumatology Unit AOU S.Anna, Ferrara, Italy, 10A.O. Rummo, Benevento, Italy, 11Sapienza University of Rome, Rome, Italy, 12Sapienza University of Rome, Italy, Roma, Italy, 13University of Siena, Siena, Italy

    Background/Purpose: This study is a sub-analysis of the data from the patient cohort of STARTER (The Sonographic Tenosynovitis Assessment in RheumaToid arthritis patiEnts in Remission)…
  • Abstract Number: 2174 • 2016 ACR/ARHP Annual Meeting

    Effect of Anti-Rheumatic Treatment on Selenium Levels in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

    Gia Deyab1, Ingrid Hokstad2, Milada Cvancarova Småstuen3, Stefan Agewall4, Jon Elling Whist5 and Ivana Hollan5,6,7,8, 1Department of Medical Biochemistry, Innlandet Hospital Trust, Lillehammer, Norway, 2Lillehammer Hospitat for Rheumatic Diseases, Lillehammer, Norway, 3Institution of health care - Health science PhD program, Oslo and Akershus University College, Oslo, Norway, 4University of Oslo, Oslo, Norway, 5Innlandet Hospital Trust, Lillehammer, Norway, 6Brigham and Women’s Hospital, Boston, MA, 7Harvard Medical School, Boston, MA, 8Lillehammer Hospital for Rheumatic Diseases, Lillahammer, Norway

    Background/Purpose: The cause of the increased cardiovascular risk in inflammatory rheumatic diseases (IRDs) is still unclear. Intriguingly, selenium-deficiency, which might be caused by poor diet or…
  • Abstract Number: 179 • 2016 ACR/ARHP Annual Meeting

    CD11b+Gr1dimcells, Which Are Induced By GM-CSF Produced By Th17 and Group3 Innate Lymphoid Cell, May Facilitate the Progression of Pneumonitis in SKG Mice

    Sho Sendo1, Jun Saegusa1, Takaichi Okano2, Soshi Takahashi3 and Akio Morinobu1, 1Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, 2Rheumatology and Clinical immunology, Kobe University Graduate School of Medicine, Kobe, Japan, 3Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan

    Background/Purpose: Rheumatoid lung disease is a prognostic factors of rheumatoid arthritis in human. The pathogenesis and the mechanism of rheumatoid lung disease is unclear. Zymosan…
  • Abstract Number: 2558 • 2016 ACR/ARHP Annual Meeting

    Dissociation of the Inhibitory Apoptosis Stimulating Protein of p53 (iASPP) Binding with Transcription Factor p73 Induces Synovial Fibroblast Apoptosis in the Rheumatoid Joint

    Chrong-Reen Wang1, Shih-Yao Chen1, Ai-Li Shiau2, Ming-Fei Liu1 and Chao-Liang Wu3, 1Internal Medicine, National Cheng Kung University Medical College and Hospital, Tainan, Taiwan, 2Microbiology and Immunology, National Cheng Kung University Medical College, Tainan, Taiwan, 3Biochemistry and Molecular Biology, National Cheng Kung University Medical College, Tainan, Taiwan

    Background/Purpose:   Apoptosis-resistant synovial fibroblasts (SFs) constitute the major cell component of pannus tissues in rheumatoid arthritis (RA). In tumor cells, the binding of inhibitory…
  • Abstract Number: 458 • 2016 ACR/ARHP Annual Meeting

    The TAM Receptors Axl and Mer Play a Protective Role in a Temporal and Spatial Manner in Inflammatory Arthritis

    Claire E.J. Waterborg1, Paqui G. Través2, Silke Beermann1, Marije I. Koenders1, Greg Lemke2 and Fons A.J. van de Loo1, 1Experimental Rheumatology, Radboudumc, Nijmegen, Netherlands, 2Molecular Neurobiology Laboratory, The Salk Institute for Biological Studies, La Jolla, CA

    Background/Purpose:  Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by an unrestrained inflammatory response in selective, anatomically distinct synovial joints. The innate immune system…
  • Abstract Number: 2581 • 2016 ACR/ARHP Annual Meeting

    Tripterygium Wilfordii Hook F Applied Topically in Patients with Active Rheumatoid Arthritis

    Juan Jiao1, Hai-bo Yin2, Xiao-po Tang2, Xun Gong2 and Quan Jiang1, 1Rheumatology Department, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China, 2Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China

    Background/Purpose:  Tripterygium wilfordii Hook F (TwHF), a traditional Chinese herb, is widely used in China for treating Rheumatoid Arthritis (RA), but limited only for eldly…
  • Abstract Number: 460 • 2016 ACR/ARHP Annual Meeting

    TAS5315, a Novel Bruton’s Tyrosine Kinase Inhibitor, Demonstrates Anti-Inflammatory Effect in Autoimmune Disease Models

    Yohei Yoshiga1, Fumihito Hosoi1, Satoru Iguchi1, Ryuusuke Kaneko1, Yoshinori Nakachi1, Daichi Akasaka1, Kenji Tanaka2, Kazuhiko Yonekura2, Teruhiro Utsugi2, Eiji Sasaki2 and Yoshikazu Iwasawa2, 1TAIHO PHARMACEUTICAL CO., LTD., TSUKUBA, Japan, 2TAIHO PHARMACEUTICAL CO., LTD., Tsukuba, Japan

    Background/Purpose:  Bruton’s Tyrosine Kinase (BTK), a non-receptor tyrosine kinase is involved in intracellular signaling pathways downstream of several receptors, including the B cell receptor (BCR),…
  • Abstract Number: 2656 • 2016 ACR/ARHP Annual Meeting

    Resume of Biologic Therapy after Tuberculosis Infection in Patients with Inflammatory Arthropathies. Daily Clinical Practice Data from an Endemic Country

    Liliana Uribe Botero1, Margarita A Saldarriaga Alvarez1, Natalia Duque Zapata1, Johnny Urrego1, Oscar Jair Felipe Diaz1, Carmen Cerón2, Alejandro Uribe1, Luis Alonso Gonzalez1,3 and José A. Gómez-Puerta1, 1Medicarte IPS, Medellín, Colombia, Medellín, Colombia, 2Medicarte IPS, Medellín, Colombia, 3Rheumatology Unit, Universidad de Antioquia, Medellin, Colombia

    Background/Purpose:  Long-term extension studies and observational drug registers mainly from Western countries or non-endemic areas have reported an increased risk of tuberculosis (TB) infection in…
  • Abstract Number: 485 • 2016 ACR/ARHP Annual Meeting

    Sexual Dimorphism of Popliteal Lymph Node Collapse As a Biomarker of Disease Progression in the Tumor Necrosis Factor Transgenic Mouse Model of Rheumatoid Arthritis

    Emily Wu1, Richard Bell2, Christopher Rudmann3, Ronald Wood4, Christopher T. Ritchlin5, Homaira Rahimi6 and Edward Schwarz7, 1Department of Immunology, Microbiology, and Virology, University of Rochester, Rochester, NY, 2Pathology, University of Rochester, Rochester, NY, 3Biological Sciences, Carnegie Mellon University, Pittsburgh, PA, 4University of Rochester, Rochester, NY, 5Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, 6Rheumatology, University of Rochester/Golisano Children's Hosp, Rochester, NY, 7Orthopedeatrics, University of Rochester, Rochester, NY

    Background/Purpose: Although rheumatoid arthritis (RA) tends to occur earlier and with increased severity in females, the underling etiology of this sexual dimorphism is unknown. We…
  • Abstract Number: 3011 • 2016 ACR/ARHP Annual Meeting

    Long-Term Outcomes after Disease Activity Guided Tapering of Tumor Necrosis Factor Inhibition in Rheumatoid Arthritis: 3 Year Data of a Randomised Controlled Pragmatic Non Inferiority Strategy Study

    Alfons A. den Broeder1, Chantal A.M. Bouman1, Frank H.J. van den Hoogen1,2, Jaap Fransen2, Ronald F. van Vollenhoven3, Johannes W.J. Bijlsma4, Aatke van der Maas1 and Noortje van Herwaarden1, 1Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, 2Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, 3Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands, 4Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands

    Long-term Outcomes After Disease Activity Guided Tapering of TNF Inhibitors in Rheumatoid Arthritis: 3 Year Data of a Randomized Controlled Pragmatic Non Inferiority Strategy Study…
  • Abstract Number: 497 • 2016 ACR/ARHP Annual Meeting

    The Identification of an ACR Score with the Optimal Discriminatory Ability Between Treatments in Patients with Early and Established Rheumatoid Arthritis

    Josef Smolen1, Roy Fleischmann2, Daniel Aletaha3, Yihan Li4, Stefan Florentinus4 and Ivan Lagunes Galindo4, 1Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 2Medicine, University of Texas Southwestern Medical Center, Dallas, TX, 3Medical University Vienna and Hietzing Hospital, Vienna, Austria, 4AbbVie Inc., North Chicago, IL

                                                                                                                           Background/Purpose: In patients (pts) with rheumatoid arthritis (RA), the American College of Rheumatology (ACR)20 score was developed to best discriminate effective from placebo…
  • Abstract Number: 3026 • 2016 ACR/ARHP Annual Meeting

    The Efficacy and Safety of Low Dose IL-2 Therapy in over-Treated Patients with Rheumatoid Arthritis: A Preliminary Study

    Sheng-Xiao Zhang1, Miao Miao2, Xiao-Qing Liu2, Xiao-Wen Ma2, Xiao-Yan Wu2 and Xiao-Feng Li1, 1Rheumatology, The Second Hospital of Shanxi Medical University, Taiyuan, China, 2The Second Hospital of Shanxi Medical University, Taiyuan, China

    Background/Purpose: Current therapy for rheumatoid arthritis (RA) often leads to excessive immunosuppression induced by glucocorticoids and DMARDs. Low-dose Interleukin 2 (IL-2) has been showed to induce…
  • Abstract Number: 575 • 2016 ACR/ARHP Annual Meeting

    Differences in Histological Scores and Histoclinical Correlations in ACPA- Versus ACPA+ Rheumatoid Arthritis Patients

    Fadil Pirbuccus1, Christine Galant1, Adrien Nzeusseu Toukap2, Frédéric A. Houssiau1, Patrick Durez2 and Bernard R. Lauwerys1, 1Pôle de pathologies rhumatismales inflammatoires et systémiques, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, 2Pôle de Maladies Rhumatismales, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium

    Background/Purpose:  Differences in the pathogenesis of ACPA- versus ACPA+ rheumatoid arthritis are still poorly understood. In this study, we compared patterns of synovial changes in…
  • Abstract Number: 3124 • 2016 ACR/ARHP Annual Meeting

    Huntingtin Interacting Protein 1 (Hip1) Is a New Arthritis Severity Gene

    Teresina Laragione1, Percio Gulko1 and Max Brenner2, 1Medicine/Rheumatology, Icahn School of Medicine at Mount Sinai, New York, NY, 2Feinstein Institute for Medical Research, Manhasset, NY

    Background/Purpose:  Cia25/Pia42 is an arthritis severity and joint damage quantitative trait locus on rat chromosome 12 previously identified in an intercross between MHC identical but…
  • Abstract Number: 1036 • 2016 ACR/ARHP Annual Meeting

    Dominant B-Cell Receptor Clones in Peripheral Blood Predict Onset of Arthritis in Individuals at Risk for Rheumatoid Arthritis

    Paul-Peter Tak1,2,3, Marieke E. Doorenspleet4, Maria de Hair5, Paul L. Klarenbeek6, Marian van Beers-Tas7, Antoine H.C. van Kampen8, Dirkjan van Schaardenburg9,10, Danielle M. Gerlag11,12, Frank Baas13 and Niek de Vries14, 1Clinical Immunology & Rheumatology F4.105, Amsterdam Rheumatology and Immunology Center, Department of Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, 2Currently: GlaxoSmithKline, Stevenage, UK, Stevenage, United Kingdom, 3currently: Ghent University, Ghent, Belgium & Cambridge University, Cambridge, United Kingdom, 4Dept. of Clinical Immunology & Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 5Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 6Dept. of Clinical Immunology & Rheumatology, Amsterdam Rheumatology and immunology Center | Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 7Rheumatology, Amsterdam Rheumatology & Immunology Center, Reade, Amsterdam, Netherlands, 8Dept Clin Epidemiology, Biostatistics & Bioinformatics, Academic Medical Center/Univ. of Amsterdam, Amsterdam, Netherlands, 9Clinical Immunology & Rheumatology F4.105, Amsterdam Rheumatology and immunology Center | Academic Medical Center, Amsterdam, Netherlands, Amsterdam, Netherlands, 10Rheumatology, Amsterdam Rheumatology and immunology Center, location Reade, Amsterdam, Netherlands, Amsterdam, Netherlands, 11Clinical Immunology & Rheumatology, ARC | Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, 12Current address: GSK,Clinical Unit Cambridge,R&D Projects Clinical Platforms & Sciences, Cambridge, United Kingdom, 13Department of Genome Analysis, Academic Medical Center/Univ. of Amsterdam, Amsterdam, Netherlands, 14Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands

    Background/Purpose: The onset of seropositive rheumatoid arthritis (RA) is preceded by the presence of specific autoantibodies in the absence of synovial inflammation. Only a subset…
  • « Previous Page
  • 1
  • …
  • 172
  • 173
  • 174
  • 175
  • 176
  • …
  • 188
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology